Flu Vaccine Aims at Constant Target 

 Like a shape-shifter in a science fiction novel, the virus that causes influenza can morph into new forms. Mutations that alter the structure of proteins on its surface enable the virus to evade its host's immune system. Host antibodies search in vain for the flu virus versions that they had encountered previously.

 A new study points to an unchanging viral feature that the immune system might be trained to detect.

 The conserved protein, called M2, is dwarfed by its neighbors, hemagglutinin and neuraminidase. These capricious, larger molecules have made the flu virus a moving target. Scientists track changes in these proteins to redesign the flu vaccine annually, so they can reeducate immune cells to prepare for a new onslaught. The vaccines, however, only represent health authorities' best guess at what form the flu virus will take as it spreads in Europe and the Americas.

 The viruses that cause all forms of influenza A, the most severe flu, display the same M2 surface protein. By bonding the little M2 to a protein from a hepatitis B virus, Belgian scientists have built a molecule that attracts the attention of the immune system in mice. Confronted by this combination protein, immune cells make antibodies that stand ready to glom on to the M2 protein and hamper the virus' attempts to infect a host.

 In theory, whether or not the immune system recognizes the hemagglutinin or neuraminidase proteins the virus contains, it would still attack the virus' M2 site, says study coauthor Walter Fiers, a molecular biologist at the University of Ghent.

 In the Belgian experiments, all the mice contracted the flu, as evidenced by weight loss and a temperature drop, when exposed to five times the amount of flu virus needed to cause illness. Of 36 mice previously given various doses of the M2-based vaccine, 30 survived the flu, but 9 of 11 unvaccinated mice died.

 In a second experiment, all 14 mice receiving a uniform, moderate dose of vaccine survived, whereas 16 unvaccinated animals all died within 9 days, the researchers report in the October Nature Medicine. In later tests, the vaccine provided immunity against additional influenza A strains.

"It's a very interesting study," says Jeffery K. Taubenberger, a molecular pathologist at the Armed Forces Institute of Pathology in Washington, D.C. "Clearly, they show that under these circumstances, they can ameliorate the disease-not preventing infection, but making it milder."

 A separate test demonstrated that the vaccinated mice retained their immunity to the flu for 6 months, says Fiers. Antibodies in vaccinated mice hobble M2 and keep the virus from spreading from cell to cell, he says.

 While scientists can often develop a strong flu vaccine by tracking the hemagglutinin protein, their guess is sometimes off target, rendering the vaccine much less effective. Incorporating a more consistent-if less potent-M2-based component into the vaccine might prove useful in years plagued by bad guessing, Fiers says.

"It seems probable that a combination of old and new [vaccines] will be required to develop a truly 'universal' vaccine for influenza," says Edwin D. Kilbourne of the New York Medical College in Valhalla in the same issue of Nature Medicine.

 An M2 component that moderates the severity of the flu could be especially valuable in a pandemic, such as the devastating outbreaks that occurred in 1918, 1957, and 1968, says Frederick G. Hayden, a clinical virologist at the University of Virginia in Charlottesville. In those years, flu strains incorporating abrupt changes in their large surface proteins hit populations worldwide.

 The new study is "a very interesting initial set of experiments," Hayden says. He adds that the real value of an M2 vaccine won't become certain until it's tested in larger mammals.